SIRTUINS

FOCUS BIOMOLECULES

SRT1720 HCl
Activator of SIRT1 that reduced glucose levels and hyperinsulinemia in diet-induced diabetic rats via enhancement of oxidative metabolism.[1,2]

Product No: 10-4628 **5 mg** **25 mg**

Tenovin-1
Activates p53 via inhibition of SIRT1 and SIRT2.[3]

Product No: 10-2982 **5 mg** **25 mg**

Honokiol
Natural product activator of SIRT3.[4]

Product No: 10-2311 **10 mg** **50 mg**

EX-527
SIRT1 Inhibitor.[5] Clinical interest as a potential therapeutic for Huntington's disease.

Product No: 10-1083 **5 mg** **25 mg**

AK-7
SIRT2 Inhibitor. Neuroprotective in mouse models of Huntington's disease.[6]

Product No: 10-1429 **5 mg** **25 mg**

Sirtinol
General sirtuin inhibitor.[7]

Product No: 10-1336 **5 mg** **25 mg**

BML-278
Novel SIRT1 activator structurally related to dihydropyridine calcium channel blockers.[8]

Product No: 10-1063 **5 mg** **25 mg**

Resveratrol
SIRT1 Activator. Shows neuroprotective effects possible therapeutic potential in stroke and neurodegenerative diseases.[9,10]

Product No: 10-1057 **200 mg** **1 g**

Piceatannol
SIRT1 Activator.[11]

Product No: 10-2293 **5 mg** **25 mg**

Salermide
SIRT1/2 inhibitor with strong anticancer activity.[12]

Product No: 10-1514 **5 mg** **25 mg**

Sirt Act
SIRT1 activator.[13] Displays anti-inflammatory effects and improves colitis in a mouse model.[14]

Product No: 10-2595 **5 mg** **25 mg**

MDL-800
Allosteric activator of SIRT6.[15]

Product No: 10-4415 **10 mg** **50 mg**

OSS-128167
SIRT6 inhibitor.[16] Promotes cell senescence and aging in myocardial cells.[17]

Product No: 10-5197 **5 mg** **25 mg**



EX-527



OSS-128167

REFERENCES

1. Milne *et al.* (2007), Nature **450** 712
2. Feige *et al.* (2008), Cell Metab. **8** 347
3. Lain *et al.* (2008), Cancer Cell **13** 454
4. Pillai *et al.* (2015), Nat. Commun. **6** 6656
5. Napper *et al.* (2005), J. Med. Chem. **48** 8045
6. Chopra *et al.* (2012), Cell Rep. **2** 1492
7. Mai *et al.* (2005), J. Med. Chem. **48** 7789
8. Mai *et al.* (2009), J. Med. Chem. **52** 5496
9. Sun *et al.* (2010), Mol. Neurobiol. **41** 375
10. Foti Cuzzola *et al.* (2011), CNS & Neurological Disorders – Drug Targets **10** 849
11. Howitz *et al.* (2003), Nature **425** 191
12. Lara *et al.* (2009), Oncogene **28** 781
13. Nayagam *et al.* (2006) J. Biomol. Screen. **11** 959
14. Caruso *et al.* (2014), Mucosal Immunol. **7** 1467
15. Huang *et al.* (2018), Chem. Biol. **14** 1118
16. Damonte *et al.* (2017), Bioorg. Med. Chem. **25** 5849
17. Zhou *et al.* (2022), Aging (Albany) **14** 9730

400 Davis Dr. Suite 600
Plymouth Meeting, PA 19462
610-994-1134
sales@focusbiomolecules.com
focusbiomolecules.com